



Supplementary Fig. 1




Supplementary Figure 2


a




b




Supplementary Fig. 3




Supplementary Fig. 4




Supplementary Fig. 5a




Supplementary Fig. 5b




Supplementary Fig. 5c



Supplementary Fig. 5d




p-Ulk-S757




Supplementary Fig. 6b

p-Ulk-S555




Supplementary Fig. 6c

p-Beclin




Supplementary Fig. 6d


p-PI-3-K (Vps34)





Supplementary Fig. 6e



Supplementary Fig. 6f




Supplementary Fig. 7




Supplementary Fig. 8a

p-Ulk 757 (fluorescence)




Supplementary Fig. 8b

p-Beclin (fluorescence)




Supplementary Fig. 8c

p62 (fluorescence)




Supplementary Fig. 8d



Cy3-coupled secondary antibody/unspecific control staining






Supplementary Fig. 9




Supplementary Fig. 10a



Supplementary Fig. 10b



Supplementary Fig. 10c



Supplementary Fig. 11

